By Mackenzie Tatananni
Shares of Insmed surged by double digits after the global biopharmaceutical company unveiled positive results for an experimental drug trial.
Shares soared 26% to $89.32 in early trading, putting them on track for their highest close since June 29, 2001, according to Dow Jones Market Data. The S&P 500 and Nasdaq Composite were each up about 0.1%.
Insmed is working on a treatment called treprostinil palmitil inhalation powder taken once daily by patients with pulmonary arterial hypertension, a progressive disease affecting the lungs and heart.
In the latest Phase 2b study, patients saw a statistically significant 35% reduction relative to a placebo in pulmonary vascular resistance, or the amount of pushback blood encounters as it travels through the lungs to the heart.
The biopharma company pledged to immediately engage with the U.S. Food and Drug Administration regarding the design for future studies.
Insmed said it intends to launch a Phase 3 trial for patients with pulmonary hypertension associated with interstitial lung disease before the end of 2025. It plans a Phase 3 trial for patients with PAH in early 2026.
Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 10, 2025 09:52 ET (13:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。